SS-31 (elamipretide): the mitochondria-targeting tetrapeptide

SS-31, generically known as elamipretide and developed under the name MTP-131 (Bendavia), is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-2',6'-Dmt-Lys-Phe-NH2. it was rationally designed to target the inner mitochondrial membrane by exploiting the large negative electrochemical potential that healthy mitochondria maintain. once there, it binds cardiolipin, the signature phospholipid of the inner mitochondrial membrane, and through that interaction reduces reactive oxygen species production, supports electron transport chain supercomplex stability, and attenuates mitochondria-triggered cell death pathways. elamipretide received FDA approval in 2026 for primary mitochondrial myopathy following Phase 3 trial data.

what is SS-31 and how was it designed?

SS-31 is a cell-permeable, mitochondria-targeted peptide developed by Hazel Szeto and Peter Schiller at the Weill Cornell Medical College. its design used alternating aromatic and basic amino acids to create a molecule that crosses biological membranes and concentrates preferentially at negatively charged mitochondrial membranes through electrostatic attraction.

the "SS" in SS-31 stands for Szeto-Schiller, the names of its inventors. the peptide uses non-standard amino acid chemistry: D-arginine at position 1 provides a positive charge and resistance to proteolysis; 2',6'-dimethyltyrosine (Dmt) at position 2 is a modified tyrosine that enhances membrane interaction; lysine at position 3 provides additional positive charge; and phenylalanine at position 4 contributes aromatic stacking with membrane lipids. the combined effect is a peptide that carries a net +3 charge at physiologic pH, which drives electrostatic concentration at the inner mitochondrial membrane (where the electrical potential is approximately -180 mV inside), achieving roughly 1000-fold higher concentration inside mitochondria than in the cytoplasm.

this mitochondrial targeting without requiring a covalent mitochondria-targeting sequence is a key engineering innovation. earlier mitochondria-targeted antioxidants like MitoQ used covalent conjugation to a triphenylphosphonium (TPP) cation, which has its own toxicity concerns at high concentrations. SS-31 achieves targeting through peptide charge distribution without the same structural concern.

how does it work at the molecular level?

SS-31 binds cardiolipin, a unique dimeric phospholipid found almost exclusively in the inner mitochondrial membrane. cardiolipin is essential for organizing electron transport chain complexes into supercomplexes that maximize efficiency. by stabilizing cardiolipin, SS-31 reduces electron leak, lowers reactive oxygen species production, maintains ATP synthesis rates, and prevents cardiolipin-mediated apoptosis signaling via cytochrome c release.

cardiolipin is one of the most functionally important and least replaceable lipids in the cell. it constitutes roughly 20 percent of the inner mitochondrial membrane lipids and is required for the structural integrity of the electron transport chain (ETC) supercomplexes. ETC supercomplexes (sometimes called "respirasomes") are higher-order assemblies of complexes I, III, and IV that channel electrons more efficiently than the individual complexes operating independently. aging, ischemia, heart failure, and primary mitochondrial disease all disrupt cardiolipin content and structure, which destabilizes supercomplexes and reduces ETC efficiency.

Tung and colleagues published a comprehensive review of elamipretide's structure, mechanism, and therapeutic potential in 2025, providing the most current mechanistic summary [1]. Whitson and colleagues demonstrated in 2021 that elamipretide treatment attenuates age-associated post-translational modifications of heart proteins in old mice, directly connecting the cardiolipin-stabilization mechanism to aging-tissue biology [2]. in neurological disease models, Zhao and colleagues showed in 2019 that elamipretide improved mitochondrial dysfunction, synaptic impairment, and memory in a lipopolysaccharide-induced neuroinflammation model in mice [3].

clinical evidence: from Phase 1 to Phase 3

SS-31/elamipretide has been studied in multiple clinical programs including primary mitochondrial myopathy, age-related macular degeneration, heart failure with preserved ejection fraction, and Barth syndrome. the pivotal Phase 3 program (MMPOWER-3) in primary mitochondrial myopathy provided the data supporting FDA approval in 2026.

the most significant clinical evidence is from the MMPOWER-3 trial, a randomized controlled trial of elamipretide in adults with genetically confirmed primary mitochondrial myopathy, published in Neurology by Karaa and colleagues in 2023 [4]. primary mitochondrial myopathy is a severe rare disease caused by genetic defects in mitochondrial function, leading to progressive muscle weakness, fatigue, and multi-system dysfunction. MMPOWER-3 demonstrated improvements in the primary endpoint (a composite measure of physical function and patient-reported fatigue) compared with placebo over a 24-week treatment period. this trial formed the central evidence package for the FDA review that resulted in elamipretide's approval in 2026, described by Shirley in Drugs in a first-approval summary [5].

earlier in the clinical development program, Phase 1 trials explored elamipretide in age-related macular degeneration (AMD), a disease with a well-established mitochondrial pathology in retinal pigment epithelial cells. Allingham, Mettu, and Cousins published Phase 1 data from the ReCLAIM studies in 2021 examining elamipretide in intermediate AMD and noncentral geographic atrophy [6]. these were safety and preliminary efficacy studies rather than definitive outcome trials, but they established tolerability and dosing parameters in a different disease population.

the honest framing is that elamipretide's approval is for a specific rare genetic disease, not a general anti-aging or performance indication. the aging biology is scientifically compelling and is the subject of active preclinical research, but clinical aging trials with elamipretide are exploratory rather than pivotal. the gray-market supply of SS-31 for off-label performance or anti-aging use lacks any human safety dataset for those applications.

where it fits in the mitochondrial biology landscape

SS-31 represents the most clinically advanced mitochondria-targeting peptide currently in or near approval. it sits in a growing family of mitochondrial medicine approaches that also includes the endogenous mitochondrial peptides humanin and MOTS-c, NAD+ precursors that boost ETC substrate availability, and autophagy inducers like spermidine that clear damaged mitochondria.

the most direct conceptual relatives in the Peptides Academy catalog are the mitochondrially encoded peptides humanin and MOTS-c. humanin is a 21-amino-acid peptide encoded in the mitochondrial 16S rRNA gene that acts as a cytoprotective signal with anti-apoptotic and insulin-sensitizing functions. MOTS-c is a 16-amino-acid mitochondrially encoded peptide that activates AMPK and improves metabolic flexibility. both are endogenous signals produced by mitochondria in response to stress, while SS-31 is a synthetic tool designed to protect mitochondria from outside.

on the small-molecule side, NMN restores NAD+/NADH ratios to support ETC function, and spermidine clears damaged mitochondria through autophagy (mitophagy). each strategy targets a different node in mitochondrial health: SS-31 protects membrane structure, NMN replenishes substrate, and spermidine removes irreparably damaged units. for a broader view of how these approaches relate to aging biology, the free peptides and your body module provides foundational context.